Claims for Patent: 7,056,529

Summary for Patent: 7,056,529

Title:	Direct cellular energy delivery system
Abstract:	A vesicle comprises ATP and a phospholipid which is a stable vesicle former. The vesicle has a fusion rate of at least 20 vesicle fusions/second.
Inventor(s):	Ehringer; William D. (Charlestown, IN), Chien; Sufan (Floyd Knobbs, IN)
Assignee:	University of Louisville Research Foundation, Inc. (Louisville, KY)
Application Number:	10/397,048
Patent Claims:	1. A fusogenic vesicle, comprising: ATP at a concentration of 1 mM to 50 mM, a phospholipid which is a stable vesicle former, wherein the phospholipid is a phosphatidylcholine, and at least one unstable vesicle forming member wherein the unstable vesicle forming member is PEG or a polar lipid having the structure of the formula (I) which is X-L-Z2, wherein X is H or a head group comprising a polar group selected from the group consisting of formulas (III), (IV), (V), (VI), and (VII) ##STR00010## L is an alkyl, and each Z is independently H, E, or the structure of formula (XI), ##STR00011## wherein E is an alkyl or alkenyl, and when one Z is H, the other Z is not H, and wherein the vesicle has a ratio of the stable vesicle former to the unstable vesicle forming member of 1:1 to 500:1 and a fusion rate of at least 20 vesicle fusions/second. 2. The vesicle of claim 1, wherein the fusion rate is at least 10.sup.3 vesicle fusions/second. 3. A method of delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 1. 4. A method of delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 2. 5. A method for treating a wound, comprising contacting the wound with a composition comprising the vesicle of claim 1. 6. A method for treating a wound, comprising contacting the wound with a composition comprising the vesicle of claim 2. 7. The method of claim 5, wherein the composition further comprises becaplermin. 8. The vesicle of claim 1, wherein the fusion rate is at least 10.sup.6 vesicle fusions/second. 9. The vesicle of claim 1, wherein the at least one unstable vesicle forming member is PEG. 10. The method of claim 3, wherein an amount of ATP delivered to the cell is sufficient to meet metabolic demand of the cell. 11. The method of claim 4, wherein an amount of ATP delivered to the cell is sufficient to meet metabolic demand of the cell. 12. A method of preserving tissue, comprising contacting tissue with the vesicle of claim 1. 13. A method of preserving tissue, comprising contacting tissue with the vesicle of claim 2. 14. A method of improving the productivity of a bioreactor having at least one cell, comprising contacting the cell with the vesicle of claim 1. 15. A method of improving the productivity of a bioreactor having at least one cell, comprising contacting the cell with the vesicle of claim 2. 16. A vesicle, comprising ATP, at a concentration of 1 mM to 50 mM DOPC, and POPA wherein a ratio of DOPC:POPA is 1:1 to 500:1. 17. The vesicle of claim 16, wherein a ratio of DOPC:POPA is 10:1 to 100:1.

Details for Patent 7,056,529

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	12/16/1997		2022-05-14